Tenax Therapeutics, Inc. Share Price

Tenax Therapeutics, Inc. Share Price

NASDAQ: TENX | Micro Cap
$1.96
+$0.07 (3.71%) Last updated on 29 Oct, 2026 | 20:38 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Tenax Therapeutics, Inc. Stock Performance

Open
$1.89
Prev. Close
$1.89
Circuit Range
N/A
Day Range
$1.88 - $1.96
Year Range
$1.32 - $19.19
Volume
24,287
Average Traded
$1.93

Tenax Therapeutics, Inc. Share Price Today

As of 29 October 2026, Tenax Therapeutics, Inc.'s share price is $1.96. The stock opened at $1.89, compared to its previous close of $1.89. During today's trading session, Tenax Therapeutics, Inc.'s share price traded between $1.88 and $1.96, with an average price of $1.92. Over the past 52 weeks, the stock has recorded a high of $19.19 and a low of $1.32. In terms of performance, Tenax Therapeutics, Inc.'s share price has declined by 85.08% over the last six months and is down 72.88% on a year-on-year basis.

Tenax Therapeutics, Inc. Share Price Chart

Line chart of the Tenax Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 1.88 to 1.96, ending at 1.95.
$1.88$1.96
L
Show Current Price
H

Tenax Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$76.67M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.73
Revenue (TTM)
$0.00
Return On Equity (TTM)
-57.10%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-12.66%

Tenax Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$15.80-$15.54-$15.72-$17.80
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A1.65%-1.16%-13.23%

Tenax Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$11.05-$7.71-$17.60-$52.60
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A30.23%-128.27%-198.86%

About Tenax Therapeutics, Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Tenax Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.91
$1.94
+1.57%
Sep 2026
$1.78
$1.91
-12.79%
Aug 2026
$13.97
$2.19
-84.00%
Jul 2026
$14.43
$13.69
-6.01%
Jun 2026
$11.70
$14.56
+22.25%
May 2026
$12.95
$11.91
-9.08%
Apr 2026
$16.17
$13.10
-18.28%
Mar 2026
$11.76
$16.03
+33.75%
Feb 2026
$12.48
$11.98
-3.42%
Jan 2026
$12.10
$12.41
+1.97%
Dec 2025
$8.92
$12.17
+29.19%
Nov 2025
$7.26
$9.42
+30.65%

TENX Share Price FAQs